Movatterモバイル変換


[0]ホーム

URL:


Jump to content
WikipediaThe Free Encyclopedia
Search

Methallenestril

From Wikipedia, the free encyclopedia
Chemical compound
Pharmaceutical compound
Methallenestril
Clinical data
Trade namesCur-men, Ercostrol, Geklimon, Novestrine, Vallestril (also spelled Vallestrol or Vallestryl)
Other namesMethallenoestril; Methallenestrol; Methallenoestrol; Horeau's acid; Allenestrol 6-methyl ether; α,α-Dimethyl-β-ethylallenolic acid 6-methyl ether; β-Ethyl-6-methoxy-α,α-dimethyl-2-naphthalenepropionic acid
Routes of
administration
By mouth
Drug classNonsteroidal estrogen
ATC code
Identifiers
  • 3-(6-Methoxynaphthalen-2-yl)-2,2-dimethylpentanoic acid
CAS Number
PubChemCID
ChemSpider
UNII
CompTox Dashboard(EPA)
ECHA InfoCard100.007.485Edit this at Wikidata
Chemical and physical data
FormulaC18H22O3
Molar mass286.371 g·mol−1
3D model (JSmol)
  • CCC(c1ccc2cc(OC)ccc2c1)C(C)(C)C(=O)O
  • InChI=1S/C18H22O3/c1-5-16(18(2,3)17(19)20)14-7-6-13-11-15(21-4)9-8-12(13)10-14/h6-11,16H,5H2,1-4H3,(H,19,20)
  • Key:KHLJKRBMZVNZOC-UHFFFAOYSA-N
  (verify)

Methallenestril (INNTooltip International Nonproprietary Name) (brand namesCur-men,Ercostrol,Geklimon,Novestrine,Vallestril), also known asmethallenoestril (BANTooltip British Approved Name) and asmethallenestrol, as well asHoreau's acid,[1][2] is asyntheticnonsteroidal estrogen and aderivative ofallenolic acid andallenestrol (specifically, amethylether of it) that was formerly used to treatmenstrual issues but is now no longer marketed.[3][4][5][6] It is a seco-analogue ofbisdehydrodoisynolic acid, and although methallenestril is potentlyestrogenic in rats, in humans it is only weakly so in comparison.[7]Vallestril was a brand of methallenestril issued byG. D. Searle & Company in the 1950s.[8] Methallenestril is takenby mouth.[9] By the oral route, a dose of 25 mg methallenestril is approximately equivalent to 1 mgdiethylstilbestrol, 4 mgdienestrol, 20 mghexestrol, 25 mgestrone, 2.5 mgconjugated estrogens, and 0.05 mgethinylestradiol.[9]

Synthesis

[edit]

The chemical synthesis has been described:[10] Patent:[11] Unavailable methods:[12][13][14]

The Grignard reaction between 2-propionyl-6-methoxynaphthalene (promen) [2700-47-2] (1) and Ethyl 2-bromoisobutyrate [600-00-0] (2) occurs to give Ethyl beta-ethyl-beta-hydroxy-6-methoxy-alpha,alpha-dimethylnaphthalene-2-propionate [85536-81-8] (3). Dehydration of the carbinol in aqueous lye may be accompanied by saponification of the ester (although not in the patented version) to give [60533-05-3] (4). Re-esterification with diazomethane gave (5). Catalytic hydrogenation of the olefin led to PC608080 (6). Saponification of the ester completed the synthesis of Methallenestril (7).

An alternative method is described in the patent that relies on 2-cyano-6-methoxynaphthalene (cyanonerolin) [67886-70-8]. The precusor to this is described in a Hoechst patent.[15]

See also

[edit]

References

[edit]
  1. ^Heftmann E (1970).Steroid Biochemistry. Academic Press. p. 144.ISBN 9780123366504.
  2. ^Dodds EC (March 1949)."Synthetic oestrogens".The Journal of Pharmacy and Pharmacology.1 (3):137–147.doi:10.1111/j.2042-7158.1949.tb12391.x.PMID 18114509.S2CID 221921908.
  3. ^Ganellin CR, Triggle DJ (21 November 1996).Dictionary of Pharmacological Agents. CRC Press. pp. 1295–.ISBN 978-0-412-46630-4.
  4. ^Morton IK, Hall JM (6 December 2012).Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Science & Business Media. pp. 177–.ISBN 978-94-011-4439-1.
  5. ^Thomas JA, Keenan EJ (1986)."Estrogens and Estrogenic Compounds".Principles of Endocrine Pharmacology. Springer Science & Business Media. p. 136.ISBN 978-1-4684-5036-1.
  6. ^Herbai G, Ljunghall S (1983). "Normalization of hypercalcaemia of primary hyperparathyroidism by treatment with methallenestril, a synthetic oestrogen with low oestrogenicity".Urologia Internationalis.38 (6):371–373.doi:10.1159/000280925.PMID 6659184.
  7. ^Kirk RE, Othmer DF (1980).Encyclopedia of chemical technology. Wiley. p. 670.ISBN 978-0-471-02065-3.
  8. ^Catalog of Copyright Entries: Third Series. Vol. 17. Copyright Office, Library of Congress. July–December 1963. pp. 1984–.
  9. ^abSwyer GI (April 1959)."The oestrogens".British Medical Journal.1 (5128):1029–1031.doi:10.1136/bmj.1.5128.1029.PMC 1993181.PMID 13638626.
  10. ^Wieland, P., Miescher, K. (January 1948)."Abkömmlinge alkylierter β‐Naphtyl‐valeriansäuren. Über oestrogene Carbonsäuren XXVI".Helvetica Chimica Acta.31 (6):1844–1854.doi:10.1002/hlca.19480310650.
  11. ^Horeau Alain & Jacques Jean,U.S. patent 2,547,123 (1951 to Individual).
  12. ^Gay, R. et al, Bull. Soc. Chim. Fr., 1955, 955.
  13. ^Jacques; Horeau Bulletin de la Societe Chimique de France, 1948 , p. 711,715.
  14. ^Dubois,J.C. et al. Bulletin de la Societe Chimique de France, 1967 , p. 1827 – 1833.
  15. ^Theodor Papenfuhs & Kurt Gengnagel,U.S. patent 4,137,272 (1979 to Hoechst AG).
Estrogens
ERTooltip Estrogen receptor agonists
Progonadotropins
Antiestrogens
ERTooltip Estrogen receptor antagonists
(incl.SERMsTooltip selective estrogen receptor modulators/SERDsTooltip selective estrogen receptor downregulators)
Aromatase inhibitors
Antigonadotropins
Others
ERTooltip Estrogen receptor
Agonists
Mixed
(SERMsTooltip Selective estrogen receptor modulators)
Antagonists
GPERTooltip G protein-coupled estrogen receptor
Agonists
Antagonists
Unknown
Stub icon

Thisdrug article relating to thegenito-urinary system is astub. You can help Wikipedia byadding missing information.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Methallenestril&oldid=1333631384"
Categories:
Hidden categories:

[8]ページ先頭

©2009-2026 Movatter.jp